Camilla Q.
- Country
- Denmark
- Department
- Department of Oncology
Research Overview
- Evaluation of [Main Substance] in Combination with Other Agents for Patients with BRAF V600E Mutated Colorectal Cancer
- Sotorasib and Combination Therapy Versus Standard Chemotherapy in Treatment-Naïve Patients with KRAS p.G12C-Mutated Metastatic Colorectal Cancer
- Efficacy and Safety of PF-08634404 and Combination Therapy Versus Bevacizumab and Combination Therapy in Treatment-Naïve Participants With Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 80 of 237 partner sites.
Specializations
Colorectal Cancer Genetics
The investigator specializes in treating BRAF V600E-mutant metastatic colorectal cancer and KRAS G12C mutation colorectal cancer, focusing on targeted therapeutic approaches.
- Gene-specific treatment strategies
- Mutation-driven therapy selection
- Advanced molecular profiling
Expertise in combining targeted therapies with established treatments for genetic variants of colorectal cancer.
Precision Oncology
Focuses on developing personalized treatment approaches for microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) colorectal cancers.
- Immunotherapy integration
- Targeted combination therapies
- Biomarker-driven treatment
Implements innovative therapeutic combinations including targeted agents and immunotherapy.
Advanced Treatment Modalities
Explores novel approaches in treating locally advanced rectal cancer, including alternative treatment sequences and innovative therapeutic combinations.
- Neoadjuvant chemotherapy protocols
- Multimodal treatment strategies
- Advanced surgical approaches
Evaluates treatment optimization through comparative assessment of standard and experimental protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.